Absci Corporation

Good day, and thank you for standing by. Welcome to the ABSEI Q3 2024 Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Alex Khan, VP Finance and Investor Relations. Please go ahead.

Thank you. Earlier today, Abcci released financial and operating results for the quarter ended September 30, 2024. If you haven't received this news release or if you would like to be added to the company's distribution list, please send an email to investors at abpsi.com. An archived webcast of this call will be available for replay on Abpsi's investor relations website at investors.abpsi.com for at least 90 days after this call. Joining me today are Sean McLean, Abpsi's founder and CEO, and Zach Jonathan, chief financial officer and chief business officer. Christian Stegman, Abpsi's SVP of drug creation, will also join for Q&A following prepared remarks. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appear in the section entitled Forward-Looking Statements in the press release ABSEI issued today and the documents and reports filed by ABSEI from time to time with the Securities and Exchange Commission. Except as required by law, APSIDIS claims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, either because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, November 12, 2024. With that, I'll turn the call over to Sean.

Thanks, Alex. Good morning, everyone, and thank you for joining us for our third quarter business update call. Today, we are excited to discuss some of the latest progress we have made throughout our portfolio programs, both partnered and wholly owned, and share some additional information ahead of our 2024 R&D Day next month. Toward the end of last year, we entered into a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. This collaboration combines Abcide's integrated drug creation platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate. We are proud to have recently announced, approximately just six months after starting this program, achievement of the first milestone under our collaboration having delivered AI de novo antibody sequences designed using our integrated drug creation platform. In addition to the progress we have made on our collaboration with AstraZeneca and with other partners, We are pleased to be adding another new partner to our diverse list of collaborators, Twist Bioscience. As we recently announced, Abcide is collaborating with Twist to design a novel antibody using generative AI. We are very excited to be working with Twist on this innovative program. In fact, we'll share additional details on this new partnership later in the call. One month from today, on December 12th, we are excited to be hosting our 2024 R&D Day in New York City. At this event, you will hear from our executive leadership and our scientific team, as well as a series of distinguished guest speakers. We plan to share additional information about our existing internal asset programs and unveil one new asset program. For those not attending in person, a live broadcast of the full presentation and a replay will be available on our website. But before then, I'd like to take a moment now to provide an overview of the current state of each of our proprietary programs. Starting with ABS 101, our potential best-in-class T01A antibody. A few months ago, we shared results from our non-human primate studies of this program, demonstrating 2 to 3x extended half-life as compared to first-generation antibodies in clinical development, and further supporting this program's potential best-in-class profile. In our studies, ABS-101 is also observed to have an increased biodistribution in NHPs, as compared to first-generation TL1a antibodies in clinical development. And CMC studies verifies the ability to formulate ABS-101 at high concentrations of 200 milligrams per milliliter, which supports further development of subcutaneous formulation. And last month, at Festival of Biologics Year of 2024, ABSEI has presented titled Development of an AI-Designed Therapeutic Anti-TL1A Antibody for IBD. Additional data for the ABS 101 program was shared at this event and can be found on ABSEI's website within our updated corporate deck and a copy of the poster shared at the conference. We continue to advance ABS 101 through IND enabling studies as planned. and are confident in our program's ability to potentially demonstrate a truly differentiated product profile. We plan to initiate phase one clinical studies of ABS 101 in the first half of 2025 and continue to expect an interim data readout in the second half of 2025. Turning to ABS 201, our potential best-in-class dermatology program. ABS 201 is designed from an undisclosed dermatological indication with significant unmet need where the efficacy of the pharmacological standard of care is not satisfactory we believe that the target for this program is underappreciated as we could potentially be second to clinic and as we continue to anticipate selecting a development candidate for this program this year we look forward to sharing some additional data and information for this program including the target and its potential markets and indications with you all at our r d day next month Finally, ABS301, our potential first-in-class immuno-oncology program. ABS301 is a fully human antibody designed to bind against a novel target discovered through Abcide's reverse immunology platform. We anticipate completion of mode of action validation sites for ABS301 in the first half of 2025, with plans to share data for this program shortly after. As you can probably tell, We at AbSci are all very excited about the updates that we'll be sharing next month at our R&D day. Until then, as always, we remain focused on continued innovation and execution on all aspects of our platform and portfolio, all with the mission to create better biologics for patients faster. And as always, the progress we are able to achieve is a testament to the work our team does each and every day at AbSci. and reflects our platform's differentiated capabilities and AI drug creation for biologics. With that, I'll now turn the call over to Zach to walk through our new partnerships, our outlook, and provide an update on our financials. Zach.